Ipilimumab - Bristol-Myers Squibb

Drug Profile

Ipilimumab - Bristol-Myers Squibb

Alternative Names: Anti CTLA-4 monoclonal antibody - Medarex; BMS-734016; MDX-010; MDX-CTLA-4; Yervoy

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medarex
  • Developer AIO Studien gGmbH; Australian and New Zealand Urogenital and Prostate Cancer Group; Bavarian Nordic; Big Ten Cancer Research Consortium; Bristol-Myers Squibb; Dana-Farber Cancer Institute; European Thoracic Oncology Platform; Grupo Espanol Multidisciplinar de Melanoma; Intergroupe Francophone de Cancerologie Thoracique; Ludwig Institute for Cancer Research; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Northwestern University; Olivia Newton-John Cancer Research Institute; Ono Pharmaceutical; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Preregistration Renal cell carcinoma
  • Phase III Gastric cancer; Glioblastoma; Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Small cell lung cancer
  • Phase II Breast cancer; Carcinomatous meningitis; CNS cancer; Colorectal cancer; Gastrointestinal cancer; Gynaecological cancer; Hepatocellular carcinoma; Myelodysplastic syndromes; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Thyroid cancer; Urogenital cancer; Uveal melanoma
  • Phase I/II Liver cancer; Lung cancer; Solid tumours
  • No development reported Lymphoma

Most Recent Events

  • 13 Dec 2017 Preregistration for Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV)
  • 13 Dec 2017 FDA assigns PDUFA action date of 16/04/2018 for ipilimumab for Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease)
  • 13 Dec 2017 Ipilimumab - Bristol-Myers Squibb receives Breakthrough Therapy status for Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top